Search

Your search keyword '"SCARPELLINI, E."' showing total 385 results
Start Over Author "SCARPELLINI, E."
385 results on '"SCARPELLINI, E."'

55. Intestinal Permeability In Migraineurs

Author

Scarpellini, E, Ferraro, D, Lauritano, E, Merra, G, Sparano, L, Campanale, C, Gasbarrini, G, Ghirlanda, G, Di Trapani, G, Valenza, V, and Gasbarrini, A

Subjects
Settore MED/09, Settore MED/49
Published
2008

62. Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms.

Author

Scarpellini, E., Boecxstaens, V., Broers, C., Vos, R., Pauwels, A., and Tack, J.

Subjects
*GASTROESOPHAGEAL reflux treatment, *BACLOFEN, *GASTRIC acid, *SPHINCTERS, *ANALYSIS of variance, *THERAPEUTICS
Abstract

Postprandial gastroesophageal reflux (PGER) in the distal esophagus (DE) is associated with a gastric juice 'acid pocket' (AP). Baclofen reduces AP extension into the DE in healthy volunteers, in part through increased lower esophageal sphincter (LES) pressure. We aimed to verify whether baclofen also affects postprandial AP location and extent in gastroesophageal reflux disease (GERD) patients. Thirteen treatment-naive heartburnprevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40mg or placebo 30minutes preprandially. We performed pH-probe stepwise pull-throughs (PT) (1 cm/min, LES -10 to +5 cm) before and every 30 minutes from 30 minutes before up to 150 minutes after a test meal. After the meal, both after placebo and baclofen, gastric pH significantly dropped at 30, 60, 90 minutes postprandially (P: nadir pHs of 3.9 ± 0.6, 2.3 ± 0.6, 2.1 ± 0.4; B: nadir pHs of 2.5 ± 0.4, 2.8 ± 0.4, 2.5 ± 0.3; all P < 0.05). After placebo, LES pressure decreased at 60, 90 and 120 minutes postprandially (32.7 ± 6.1 vs. 24.5 ± 3.1, 27.3 ± 5.9, 27.3 ± 6.0 mmHg; analysis of variance [ANOVA], P = 0.037), but this was prevented by baclofen (25.4 ± 3.4 vs. 29.4 ± 2, 32.2 ± 1.4, 35.5 ± 1.7 mmHg, ANOVA, P = not significant (NS)). Baclofen did not significantly decrease the postprandial AP extent above the LES but prevented the postprandial increase in transient lower esophageal sphincter relaxations (TLESRs) (preprandial vs. postprandial, placebo: 1.1 ± 0.3 vs. 3.7 ± 0.7, P < 0.05; baclofen: 1.4 ± 0.4 vs. 2 ± 0.5, P = NS). In GERD patients, baclofen significantly increases postprandial LES pressure, prevents the increase TLESRs but, unlike in healthy volunteers, does not affect AP extension into the DE. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

70. Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms.

Author

Scarpellini, E., Boecxstaens, V., Broers, C., Vos, R., Pauwels, A., and Tack, J

Subjects
ESOPHAGOGASTRIC junction, BACLOFEN, TREATMENT of esophageal cancer, GASTRIC acid, GASTROESOPHAGEAL reflux, GABA receptors, SYMPTOMS, THERAPEUTICS
Abstract

Postprandial gastroesophageal reflux ( PGER) in the distal esophagus ( DE) is associated with a gastric juice 'acid pocket' ( AP). Baclofen reduces AP extension into the DE in healthy volunteers, in part through increased lower esophageal sphincter ( LES) pressure. We aimed to verify whether baclofen also affects postprandial AP location and extent in gastroesophageal reflux disease ( GERD) patients. Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially. We performed pH-probe stepwise pull-throughs ( PT) (1 cm/min, LES −10 to +5 cm) before and every 30 minutes from 30 minutes before up to 150 minutes after a test meal. After the meal, both after placebo and baclofen, gastric pH significantly dropped at 30, 60, 90 minutes postprandially ( P: nadir pHs of 3.9 ± 0.6, 2.3 ± 0.6, 2.1 ± 0.4; B: nadir pHs of 2.5 ± 0.4, 2.8 ± 0.4, 2.5 ± 0.3; all P < 0.05). After placebo, LES pressure decreased at 60, 90 and 120 minutes postprandially (32.7 ± 6.1 vs. 24.5 ± 3.1, 27.3 ± 5.9, 27.3 ± 6.0 mmHg; analysis of variance [ ANOVA], P = 0.037), but this was prevented by baclofen (25.4 ± 3.4 vs. 29.4 ± 2, 32.2 ± 1.4, 35.5 ± 1.7 mmHg, ANOVA, P = not significant (NS)). Baclofen did not significantly decrease the postprandial AP extent above the LES but prevented the postprandial increase in transient lower esophageal sphincter relaxations ( TLESRs) (preprandial vs. postprandial, placebo: 1.1 ± 0.3 vs. 3.7 ± 0.7, P < 0.05; baclofen: 1.4 ± 0.4 vs. 2 ± 0.5, P = NS). In GERD patients, baclofen significantly increases postprandial LES pressure, prevents the increase TLESRs but, unlike in healthy volunteers, does not affect AP extension into the DE. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

71. Gastrointestinal motility disorder assessment in systemic sclerosis

Author

Savarino, E., primary, Mei, F., additional, Parodi, A., additional, Ghio, M., additional, Furnari, M., additional, Gentile, A., additional, Berdini, M., additional, Di Sario, A., additional, Bendia, E., additional, Bonazzi, P., additional, Scarpellini, E., additional, Laterza, L., additional, Savarino, V., additional, and Gasbarrini, A., additional

Published
2013
Full Text
View/download PDF

74. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

Author

Lupascu, Andrea, Gabrielli, Maurizio, Lauritano, Ernesto Cristiano, Scarpellini, E., Santoliquido, Angelo, Cammarota, Giovanni, Flore, Roberto Antonio, Tondi, Paolo, Pola, Paolo, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Santoliquido, Angelo (ORCID:0000-0003-1539-4017), Cammarota, Giovanni (ORCID:0000-0002-3626-6148), Flore, Roberto Antonio (ORCID:0000-0003-1659-1338), Tondi, Paolo (ORCID:0000-0003-1654-2448), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Lupascu, Andrea, Gabrielli, Maurizio, Lauritano, Ernesto Cristiano, Scarpellini, E., Santoliquido, Angelo, Cammarota, Giovanni, Flore, Roberto Antonio, Tondi, Paolo, Pola, Paolo, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Santoliquido, Angelo (ORCID:0000-0003-1539-4017), Cammarota, Giovanni (ORCID:0000-0002-3626-6148), Flore, Roberto Antonio (ORCID:0000-0003-1659-1338), Tondi, Paolo (ORCID:0000-0003-1654-2448), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

BACKGROUND: Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exist on small intestinal bacterial overgrowth prevalence in a significant population of healthy non-irritable bowel syndrome subjects. AIM: To assess the prevalence of small intestinal bacterial overgrowth by glucose breath test in patients with irritable bowel syndrome symptoms with respect to a consistent control group. METHODS: Consecutive patients with irritable bowel syndrome according to Rome II criteria were enrolled. The control population consisted of 102 sex- and age-matched healthy subjects without irritable bowel syndrome symptoms. All subjects underwent glucose breath test. A peak of H2 values >10 p.p.m above the basal value after 50 g of glucose ingestion was considered suggestive of small intestinal bacterial overgrowth. RESULTS: A total of 65 irritable bowel syndrome patients and 102 healthy controls were enrolled. Positivity to glucose breath test was found in 31% of irritable bowel syndrome patients with respect to 4% in the control group, the difference between groups resulting statistically significant (OR: 2.65; 95% CI: 3.5-33.7, P < 0.00001). CONCLUSIONS: The present case-control study showed an epidemiological association between irritable bowel syndrome and small intestinal bacterial overgrowth. Placebo-controlled small intestinal bacterial overgrowth-eradication studies are necessary to clarify the real impact of small intestinal bacterial overgrowth on irritable bowel syndrome symptoms.

Published
2005

75. -Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth

Author

Lauritano, Ernesto Cristiano, Gabrielli, Maurizio, Lupascu, Andrea, Santoliquido, Angelo, Nucera, Gabriella, Scarpellini, E., Vincenti, F., Cammarota, Giovanni, Flore, Roberto Antonio, Pola, Paolo, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Santoliquido, Angelo (ORCID:0000-0003-1539-4017), Cammarota, Giovanni (ORCID:0000-0002-3626-6148), Flore, Roberto Antonio (ORCID:0000-0003-1659-1338), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Lauritano, Ernesto Cristiano, Gabrielli, Maurizio, Lupascu, Andrea, Santoliquido, Angelo, Nucera, Gabriella, Scarpellini, E., Vincenti, F., Cammarota, Giovanni, Flore, Roberto Antonio, Pola, Paolo, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Santoliquido, Angelo (ORCID:0000-0003-1539-4017), Cammarota, Giovanni (ORCID:0000-0002-3626-6148), Flore, Roberto Antonio (ORCID:0000-0003-1659-1338), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

BACKGROUND: Few controlled studies assessing choice and duration of antibiotic therapy for small intestinal bacterial overgrowth are available. AIM: To assess efficacy, safety and tolerability of different doses of rifaximin, a broad spectrum non-absorbable antibiotic, for intestinal bacterial overgrowth eradication. METHODS: We enrolled 90 consecutive patients affected by small intestinal bacterial overgrowth. The presence of small intestinal bacterial overgrowth was based on the occurrence of a rise of H2 values >12 p.p.m. above the basal value after 50 g glucose ingestion. Patients were randomized in three 7-day treatment groups: rifaximin 600 mg/day (group 1); rifaximin 800 mg/day (group 2) and rifaximin 1200 mg/day (group 3). Glucose breath test was reassessed 1 month after the end of therapy. Compliance to the treatment and incidence of side-effects were also evaluated. RESULTS: No drop-outs were observed in the three groups. Glucose breath test normalization rate was significantly higher in group 3 (60%) with respect to group 1 (17%; P < 0.001) and group 2 (27%, P < 0.01). No significant differences in patient compliance and incidence of side-effects were found among groups. CONCLUSIONS: Higher doses of rifaximin lead to a significant gain in terms of therapeutic efficacy in small intestinal bacterial overgrowth eradication without increasing the incidence of side-effects.

Published
2005

78. P.18.11 THE IMPACT OF ANXIETY ON LACTOSE INTOLERANCE SYMPTOMS

Author

Ojetti, V., primary, Bertucci, F., additional, Ianiro, G., additional, Tortora, A., additional, Buccelletti, F., additional, Gerardi, V., additional, Ferrarese, D., additional, Scarpellini, E., additional, Gabrielli, M., additional, Gigante, G., additional, and Gasbarrini, A., additional

Published
2012
Full Text
View/download PDF

89. P.1.181: ACCURACY OF CO2 CORRECTED H2 AND CH4 VALUES IN BREATH TESTS

Author

Campanale, M., primary, Scarpellini, E., additional, Tortora, A., additional, Bertucci, F., additional, Purchiaroni, F., additional, Maurizio, G., additional, Lauritano, C.E., additional, Di Maurizio, L., additional, Ojetti, V., additional, Gasbarrini, G., additional, Bombardieri, G., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

95. 51Cr-EDTA permeability test in ascitic cirrhotic patients with and without history of spontaneous bacterial peritonitis

Author

Scarpellini, E., primary, Merra, G., additional, Dal Lago, A., additional, Zileri Dal Verme, L., additional, Lauritano, C., additional, Petruzzellis, C., additional, Finizio, R., additional, Santoro, M., additional, Garcovich, M., additional, Lupascu, A., additional, Gasbarrini, G., additional, Ghirlanda, G., additional, Valenza, V., additional, and Gasbarrini, A., additional

Published
2009
Full Text
View/download PDF

96. INTESTINAL PERMEABILITY IN MIGRAINEURS

Author

Scarpellini, E., primary, Ferraro, D., additional, Lauritano, C., additional, Ojetti, V., additional, Vitale, G., additional, Sparano, L., additional, Fiore, F., additional, Campanale, C., additional, Ghirlanda, G., additional, Di Trapani, G., additional, Valenza, V., additional, and Gasbarrini, A., additional

Published
2009
Full Text
View/download PDF

100. S1269 Small Intestinal Bacterial Overgrowth in a Children Population Affected By Irritable Bowel Syndrome: A Case-Control Study

Author

Scarpellini, E., primary, Fundarò, C., additional, Giorgio, V., additional, Pantanella, A., additional, Cesario, V., additional, Lauritano, Ernesto Cristiano, additional, Roccarina, Davide, additional, Novi, Marialuisa, additional, Ainora, M., additional, Garcovich, M., additional, Gigante, Giovanni, additional, Cammarota, Giovanni, additional, Gasbarrini, Giovanni, additional, Ghirlanda, Giovanni, additional, and Gasbarrini, Antonio, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results